Clinical Trial

A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center

Recruiting
View on ClinicalTrials.gov →
Summary
Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \[1\].
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-18; most recent amendment 2026-04-27.
Trial Details
NCT Number NCT06095440
Lead Sponsor Methodist Health System
Conditions Hepatorenal Syndrome
Enrollment 500 participants
Start Date 2023-05-13
Primary Completion 2027-05-13 (estimated)
Study Completion 2027-05-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-01